MDX Meldex

    RNS Number : 0815F
  Meldex International PLC
  03 October 2008
   

    Correction

    The following amendment has been made to the announcement released today with RNS number 9120E. The placing price and amount raised were
omitted from the details of the shares being issued pursuant to a placing for cash. All other details remain unchanged.

    The full amended text is shown below.


    Meldex International plc
    ("Meldex International" or the "Company")

    Application for listing 

    London, UK, 03 October 2008, Meldex International (AIM: MDX) the specialty pharma and healthcare company, announces,  that application
has been made to AIM Market of the London Stock Exchange, for the admission to trading of 7,738,008 ordinary shares of 1p each in the
Company (the "New Ordinary Shares").

    The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Of the 7,738,008 ordinary shares
allotted: 1,322,822 New Ordinary Shares are being issued in relation to a placing for cash at 42.5p per share to raise �562,199.14, which
will be utilised to satisfy long term obligations of the Company incurred in connection with activities pertaining to Intellectual Property
development; 3,570,543 New Ordinary Shares were allotted as vendor consideration to satisfy the Company's long term obligations in the
purchase of pharmaceutical registration dossiers from ICE Healthcare Limited; 2,844,643 New Ordinary Shares were allotted as the third
installment of vendor consideration for the acquisition of the Alfatil, Alphexine and Cephaclor pharmaceutical products (the 'Products')
from Laboratoires Tonipharm and to satisfy other commercial obligations of the Company connected thereto. This issue of the third
installment of shares to Laboratoires Tonipharm is as a result of sales of the Products reaching specific milestones which were set when the Company entered into the agreement for the acquisition of the Products in
December 2007 (See RNS News Announcement dated 24 December 2008).

    It should be noted that the Directors have authorised the allotment and issue of the New Ordinary Shares based on the authority given to
them at the AGM held in 2007. This is because the obligations to issue the New Ordinary Shares arose prior to the AGM held in 2008,
therefore the Directors are entitled to allot and issue these shares as if the authority to do so had not expired at the last AGM held in
2008.

    Trading in the New Ordinary Shares on AIM is expected to commence on or around 07 October 2008.

    The total number of share in issue following admission of the New Ordinary Shares is 232,541,089. There are no shares are held in
treasury. Therefore, the total number of voting rights in the Company is 232,541,089. 



    For further information:

    Buchanan Communications                             + 44 (0) 20 7466 5000
    Rebecca Skye Dietrich

    FinnCap, NOMAD                                             + 44 (0) 20 7600 1658
    Geoff Nash 




    About Meldex International Plc
    Meldex International plc is an innovative specialty pharmaceutical and OTC product Company. Listed on London's AIM in May 2003, the
Company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic
alliances with several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007. Melbrosin's focus is on consumer over
the counter health care products based on substances of natural and plant origin which are developed into consumer orientated brands then
scaled, produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and marketing business
created and expanded in 2006.

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGEL� polymer technology. For further information please go to www.meldexinternational.com





This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
IOEMJBITMMTMBBP

Meldex (LSE:MDX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Meldex (LSE:MDX)
Historical Stock Chart
From Jul 2023 to Jul 2024